Tech Company Financing Transactions
MPC Therapeutics Funding Round
MPC Therapeutics secured a $1.6 million Seed funding round on 1/11/2023. Investors included Plutus Investment Group.
Transaction Overview
Company Name
Announced On
1/11/2023
Transaction Type
Venture Equity
Amount
$1,630,000
Round
Seed
Investors
Plutus Investment Group (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its proprietary small molecule towards clinical trials and open new therapeutic applications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Chemin des Aulx 14
Plan-les-Ouates, CH1228
CH
Plan-les-Ouates, CH1228
CH
Phone
Undisclosed
Website
Email Address
Overview
MPC Therapeutics is a biotechnology company founded on the belief that mitochondria, small organelles at the core of the cell's metabolism, represent untapped therapeutic targets. Using our deep understanding of mitochondrial biology and medicinal chemistry, our mission is to develop a new generation of small molecules able to modulate mitochondrial functions in order to change the cell's behavior and reverse the course of diseases. Headquartered in Switzerland, MPC Therapeutics is currently focused on developing life-changing drugs for patients with cancer and degenerative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Raphael Martinou
Chief Scientific Officer
Jean Martinou
Co-Founder
Benjamin Perry
Browse more venture capital transactions:
Prev: 1/11/2023: Kiavi venture capital transaction
Next: 1/11/2023: Butter Payments venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs